2008
DOI: 10.1074/jbc.m805296200
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro Activation of the Rhesus Macaque Myeloid α-Defensin Precursor proRMAD-4 by Neutrophil Serine Proteinases

Abstract: -94) resists NE, CG, and P3 proteolysis completely, RMAD-4 (62-94) variants with disulfide pairing disruptions or lacking disulfide bonds were degraded extensively, evidence that the disulfide array protects the ␣-defensin moiety from degradation by the myeloid converting enzymes. These in vitro analyses support the conclusion that rhesus macaque myeloid pro-␣-defensins are converted to active forms by serine proteinases that co-localize in azurophil granules.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
37
0

Year Published

2009
2009
2015
2015

Publication Types

Select...
6
2

Relationship

4
4

Authors

Journals

citations
Cited by 19 publications
(39 citation statements)
references
References 31 publications
2
37
0
Order By: Relevance
“…In this respect, Crp4 and RMAD-4 (rhesus myeloid ␣-defensin-4) differ markedly with regard to charge distribution and the orientation of hydrophobic side chains along the peptide fold. Still, neutralizing anionic amino acids in the proregion of pro-RMAD-4-(20 -94) have the same activating effects as those described here for pro-Crp4-(20 -92) (36). Possibly, the biochemistry of the HNP precursor may have a unique structural context, leaving the question open until additional molecules have been characterized.…”
Section: Discussionmentioning
confidence: 63%
“…In this respect, Crp4 and RMAD-4 (rhesus myeloid ␣-defensin-4) differ markedly with regard to charge distribution and the orientation of hydrophobic side chains along the peptide fold. Still, neutralizing anionic amino acids in the proregion of pro-RMAD-4-(20 -94) have the same activating effects as those described here for pro-Crp4-(20 -92) (36). Possibly, the biochemistry of the HNP precursor may have a unique structural context, leaving the question open until additional molecules have been characterized.…”
Section: Discussionmentioning
confidence: 63%
“…Recombinant proteins were expressed and purified as His 6 -tagged fusion proteins as described previously (34,37). Expression of recombinant fusion proteins was induced by adjusting exponentially growing E. coli BL21-CodonPlus (DE3)-RIL cells with 0.1 mM isopropyl-␤-D-1-thiogalactopyranoside and incubating them at 37°C for 6 h in Terrific broth as described in earlier reports (14,34,37). Cells were lysed by sonication in 6 M guanidineHCl-100 mM Tris (pH 8.0), and the suspension was clarified by centrifugation.…”
Section: Methodsmentioning
confidence: 99%
“…Samples of proCrp4 and (R/K)-proCrp4 (11 g) and of Crp4 and (R/K)-Crp4 (5 g) were incubated with or without 0.5 molar equivalents of MMP-7 in 1 mM HEPES, 15 mM NaCl, and 0.5 mM CaCl 2 (pH 7.4) for 18 h at 37°C. Similarly, samples of proCrp4 (12 g) and Crp4, (R/K)-Crp4, RMAD-4, and (R/K)-RMAD-4 (6 g) were incubated with human neutrophil elastase in 50 mM Tris-150 mM NaCl (pH 7.5) at 37°C for 2 h at a substrate:enzyme ratio of 40:1 (14). Twelve micrograms of proCrp4 and 6 g of Crp4, (R/K)-Crp4, RMAD-4, and (R/K)-RMAD-4 were incubated with bovine pancreatic trypsin (Sigma-Aldrich, St. Louis, MO) in 50 mM ammonium bicarbonate at a 1:50 proteinase-to-protein ratio for 2 h. Peptide sensitivity to proteolysis was assayed by Coomassie blue staining of peptide digests following AU-PAGE separations (14,20,34).…”
Section: Methodsmentioning
confidence: 99%
“…To test whether positioning of hydrophobic residues as shown for Crp-4 is a general requirement for ␣-defensin bactericidal activity, we tested the effect of modifying hydrophobicity in RMAD-4. RMAD-4 was selected for study, because it has the same overall bactericidal activity (19,28,36) and cationic charge as Crp-4 (ϩ8), but RMAD-4 differs from Crp-4 in primary structure and in the distribution of peptide surface charge (Fig. 2) (19).…”
Section: Resultsmentioning
confidence: 99%
“…Crp-4 and RMAD-4 peptides were prepared as described previously (24)(25)(26)(27)(28). Briefly, recombinant peptides were expressed in E. coli as His 6 -tagged fusion proteins using the pET28a expression vector (Novagen, Inc., Madison, WI) at the EcoRI and SalI sites.…”
Section: Methodsmentioning
confidence: 99%